Shareholders who lost money in shares of Zynex, Inc. (OTCMKTS: ZYXIQ) should contact Wolf Haldenstein immediately

Core Allegations - A class action lawsuit has been filed against Zynex, Inc. for alleged violations of federal securities laws due to materially false and misleading statements and omissions [2][3] - The complaint claims that Zynex shipped products, including electrodes, in excess of medical necessity, leading to inflated reported revenue [2][8] - The company's billing practices have drawn scrutiny from insurers, including Tricare, and have been linked to a fraudulent overbilling scheme [8] Legal Context - Investors who purchased Zynex shares between February 25, 2021, and December 15, 2025, have until April 21, 2026, to seek appointment as lead plaintiff [1][4] - The law firm Wolf Haldenstein Adler Freeman & Herz LLP is representing the class action, emphasizing their extensive experience in securities litigation [6] Compliance and Regulatory Issues - Allegations include that Zynex management prioritized aggressive sales growth over regulatory compliance and failed to maintain strong internal controls [8] - The company faces foreseeable risks such as removal from insurer networks and federal government penalties due to these practices [8]